Your browser doesn't support javascript.
loading
In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.
Mak, Lung-Yi; Liu, Sze-Hang; Yap, Desmond Yat-Hin; Seto, Wai-Kay; Wong, Danny Ka-Ho; Fung, James; Chan, Tak-Mao; Lai, Ching-Lung; Yuen, Man-Fung.
Afiliación
  • Mak LY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
  • Liu SH; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
  • Yap DY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
  • Seto WK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
  • Wong DK; State Key Laboratory for Liver Research, The University of Hong Kong, Pokfulam, Hong Kong.
  • Fung J; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
  • Chan TM; State Key Laboratory for Liver Research, The University of Hong Kong, Pokfulam, Hong Kong.
  • Lai CL; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road 102, Pokfulam, Hong Kong.
  • Yuen MF; State Key Laboratory for Liver Research, The University of Hong Kong, Pokfulam, Hong Kong.
Dig Dis Sci ; 64(12): 3630-3641, 2019 12.
Article en En | MEDLINE | ID: mdl-31280390
AIM: Renal toxicity of adefovir disoproxil (ADV) and tenofovir disoproxil fumarate (TDF) is a significant concern in chronic hepatitis B (CHB) patients. Early observational clinical data suggested that telbivudine (LdT) might have renoprotective effects. METHODS: In this prospective study, consecutive CHB patients on combined lamivudine (LAM) + ADV/TDF were switched to LdT + ADV/TDF at recruitment and were followed up for 24 months. Estimated glomerular filtration rate (eGFR) was calculated with the modification of diet in renal disease equation. The effects of LdT on cell viability and expression of kidney injury or apoptotic biomarkers were investigated in cultured renal tubular epithelial cell line HK-2. RESULTS: Thirty-one patients (median age 55 years, 90.3% male) were recruited (54.8% TDF: 45.2% ADV). Serum HBV DNA was undetectable at all time points. Median eGFR was 70.2 (IQR 62.6-77.9) and 81.5 (IQR 63.6-99.1) mL/min/1.73 m2 at baseline and 24 months, respectively (p < 0.001). Downstaging of chronic kidney disease was observed in eight (25.8%) patients and was more common in ADV-treated compared to TDF-treated patients (7/8 vs. 1/17, p = 0.011; OR 16, 95% CI 1.643-155.766, p = 0.017). In vitro data showed that adding LdT to ADV or TDF was associated with improved cell viability and lower expression of injury and apoptotic biomarkers compared with ADV or TDF alone. Treatment was prematurely discontinued in four(12.9%) patients due to myalgia. CONCLUSIONS: Clinical and in vitro data suggest that LdT has renoprotective effects in patients on long-term ADV/TDF treatment. LdT may be considered as an adjuvant therapy in this special group of patients with renal impairment (NCT03778567).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Adenina / Hepatitis B Crónica / Insuficiencia Renal Crónica / Organofosfonatos / Tenofovir / Telbivudina / Tasa de Filtración Glomerular Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Dig Dis Sci Año: 2019 Tipo del documento: Article País de afiliación: Hong Kong Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Adenina / Hepatitis B Crónica / Insuficiencia Renal Crónica / Organofosfonatos / Tenofovir / Telbivudina / Tasa de Filtración Glomerular Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Dig Dis Sci Año: 2019 Tipo del documento: Article País de afiliación: Hong Kong Pais de publicación: Estados Unidos